NEW YORK (GenomeWeb News) – Becton Dickinson and Fujirebio Diagnostics have inked a worldwide development and supply agreement for multiplex oncology diagnostic assays.
The firms said today that they will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform. Initial efforts will focus on the ovarian cancer biomarker HE4, which is cleared by the Food and Drug Administration for monitoring the progression or recurrence of epithelial ovarian cancer.
In addition, Fujirebio granted to BD access to other cancer biomarkers for use on BD's TriPath testing platform.
"By incorporating Fujirebio Diagnostics' cancer biomarkers within our own cancer diagnostics development program, we believe that we are poised to provide clinicians with innovative diagnostic tools for improved patient management and contribute to BD's growth in cancer diagnostics," Wayhne Brinster, VP and GM for women's health and cancer at BD, said in a statement.
Financial and other terms of the collaboration were not disclosed.